Country Access Report
Switzerland has limited medical access rather than general psychedelic medicine approval. Physicians can seek FOPH exceptional permissions for limited medical use of prohibited narcotics such as LSD, psilocybin and MDMA, but this is case-by-case, non-routine and generally outside compulsory health-insurance reimbursement. Spravato is the main authorised and reimbursed psychedelic-adjacent psychiatric medicine, with Specialities List coverage from 1 October 2025 under prior-approval and centre restrictions. Ketamine is available as an anaesthetic but not authorised or routinely reimbursed as a depression medicine.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Psilocybin can be used only through FOPH exceptional permission for limited medical use of prohibited narcotics, applied for by the treating physician with patient consent and Swiss residency requirements. The 2025 BAG expert report describes psilocybin permissions as increasing since 2021, but these treatments are not Swissmedic-authorised products and are not routine compulsory-insurance benefits. [1] [2]
Compound Access
MDMA can be used only through FOPH exceptional permission for limited medical use or through research approvals, not as a generally authorised Swissmedic medicine. The physician-led exception pathway requires an individual application and does not create routine health-insurance reimbursement. [1] [2]
Compound Access
Compound Access
Ketamine is available as an anaesthetic medicine, but psychiatric use for depression is not the same as Spravato reimbursement. FOPH's 2023 KLV commentary notes that adding ketamine hydrochloride to the tariff for depression and pain was rejected, so reimbursement remains case- and setting-dependent rather than a general depression pathway. [1]
Compound Access
DMT is controlled in Switzerland. Swissmedic clarified that N,N-DMT is listed as a prohibited controlled substance and that DMT-containing preparations require product-specific assessment; Swiss research has studied DMT, but no routine medical access or reimbursement pathway was verified. [1] [2] [3]
Compound Access
Compound Access
No authorised or reimbursed medical pathway for ibogaine was verified in the reviewed Swiss primary sources. Any patient-access claim would need direct evidence of an FOPH exception, Swissmedic authorisation or approved study. [1]
Compound Access
Ayahuasca is legally sensitive because DMT is controlled while DMT-containing plants are not listed in the same way. Swissmedic's clarification says DMT-containing preparations can still fall under narcotics control depending on product, presentation and context, with cantonal authorities assessing individual cases. No routine medical or reimbursed pathway was verified. [1]
Compound Access
Compound Access
2C-B has appeared in Swiss healthy-volunteer research, including a completed comparison study with MDMA and psilocybin, but registry research is not medical access. No authorised or reimbursed 2C-compound pathway was verified. [1]
Last updated 6 May 2026. Source links come from the medical access guide.